UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: August 30, 2021

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ☐

Legend Biotech to Participate in the Morgan Stanley 19^th^ Annual Global Healthcare Conference

Legend Biotech Corporation (“Legend Biotech”) will participate in the Morgan Stanley 19^th^ Annual Global Healthcare Conference (Virtual) on September 10, 2021.  Legend Biotech will be represented by Ying Huang, Chief Executive Officer and Chief Financial Officer, at a session scheduled at 8:45 a.m. (Eastern time).

The webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Legend Biotech to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--August 30, 2021--Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19^th^ Annual Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10. Ying Huang, Chief Executive Officer and Chief Financial Officer, will represent the Company in a session scheduled at 8:45 a.m. (Eastern Time).

The webcast will be available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Contacts

Investor Contacts:

          Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech 

          jessie.yeung@legendbiotech.com or investor@legendbiotech.com

          Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech 

          crystal.chen@legendbiotech.com

          **Press Contact:** 

          Tina Carter, Corporate Communications Lead, Legend Biotech 

          tina.carter@legendbiotech.com or media@legendbiotech.com